PASSAGE BIO, INC. Contract Liability (Deferred Revenue)
PASSAGE BIO, INC. (PASG) had Contract Liability (Deferred Revenue) of $16.25 million as of 2026-06-30, per its S-4/A filed 2026-09-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-09-03
- 2026-06-30: Contract with Customer, Liability, Current $16.25M.
- 2026-03-31: Contract with Customer, Liability, Current $13.75M.
- 2025-12-31: Contract with Customer, Liability, Current $13.75M.
- 2025-09-30: Contract with Customer, Liability, Current $13.75M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $16.25M S-4/A · filed 2026-09-03 |
| 2026-03-31 | $13.75M S-4 · filed 2026-07-21 |
| 2025-12-31 | $13.75M S-4/A · filed 2026-09-03 |
| 2025-09-30 | $13.75M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $9.74M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $8.73M 10-Q · filed 2025-05-13 |
| 2024-12-31 | $8.23M S-4/A · filed 2026-09-03 |
| 2024-09-30 | $5.00M 10-Q · filed 2024-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |